Pikkelysömör: vizsgálatok itt: Brazília
6 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- No phaseNot yet taking people in BrazíliaCosmetic Efficacy Evaluation of Hydraporin AI Cream in Individuals With Atopic Dermatitis and Psoriasis
- Where
- Osasco
- Életkor
- 3 év to 65 év
- People
- 42
- Run by
- Brainfarma Industria Química e Farmacêutica S/A
See details and how to joinNCT07918560 - 3. fázisTaking peopleA Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Where
- Goiânia, Votuporanga
- Életkor
- 3 év to 64 év
- People
- 196 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00 - 3. fázisTaking peopleLong-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- Where
- Botucatu, Campinas, Curitiba, João Pessoa, Juiz de Fora, Porto Alegre, Ribeirão Preto, Salvador, Santo André, São José do Rio Preto, São Paulo, Vila Clementino
- Életkor
- 40 év and over
- People
- 3040 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07116967 · EU 2023-503766-24-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- Where
- Campinas, Curitiba, Porto Alegre, Ribeirão Preto, Salvador, São Paulo
- Életkor
- 12 év to 17 év
- People
- 366 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06979453 · EU 2023-506296-97-00 - 3. fázisTaking peopleA Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
- Where
- Porto Alegre, Ribeirão Preto, Rio de Janeiro, Salvador, São Paulo
- Életkor
- 4 év to 18 év
- People
- 153 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04772079 · EU 2022-502519-13-00 - 4. fázisTaking peopleSafety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
- Where
- São Paulo
- Életkor
- 12 év to 59 év
- People
- 477
- Run by
- University of Sao Paulo General Hospital
See details and how to joinNCT07087912